5 Tips about Sifalimumab You Can Use Today
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To judge various intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major trial targets had been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis sufferer